194 related articles for article (PubMed ID: 16310371)
1. Cancer of the prostate.
Bracarda S; de Cobelli O; Greco C; Prayer-Galetti T; Valdagni R; Gatta G; de Braud F; Bartsch G
Crit Rev Oncol Hematol; 2005 Dec; 56(3):379-96. PubMed ID: 16310371
[TBL] [Abstract][Full Text] [Related]
2. [Practice guideline 'Prostate cancer: diagnosis and treatment'].
de Reijke TM; Battermann JJ; van Moorselaar RJ; de Jong IJ; Visser AP; Burgers JS
Ned Tijdschr Geneeskd; 2008 Aug; 152(32):1771-5. PubMed ID: 18754308
[TBL] [Abstract][Full Text] [Related]
3. An analysis of watchful waiting for clinically localized prostate cancer.
Steinberg GD; Bales GT; Brendler CB
J Urol; 1998 May; 159(5):1431-6. PubMed ID: 9554328
[TBL] [Abstract][Full Text] [Related]
4. Do older men benefit from curative therapy of localized prostate cancer?
Alibhai SM; Naglie G; Nam R; Trachtenberg J; Krahn MD
J Clin Oncol; 2003 Sep; 21(17):3318-27. PubMed ID: 12947068
[TBL] [Abstract][Full Text] [Related]
5. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
[TBL] [Abstract][Full Text] [Related]
6. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
7. [Therapy of prostate carcinoma. Age, general health status and stage determine choice of therapy].
Otto T; Seegenschmiedt MH; Rübben H
MMW Fortschr Med; 2000 Mar; 142(11):32-4. PubMed ID: 10786086
[TBL] [Abstract][Full Text] [Related]
8. [The treatment options for localized prostate cancer].
Livne PM
Harefuah; 2006 Jan; 145(1):36-7, 77. PubMed ID: 16450723
[TBL] [Abstract][Full Text] [Related]
9. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
10. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up.
Akaza H; Homma Y; Usami M; Hirao Y; Tsushima T; Okada K; Yokoyama M; Ohashi Y; Aso Y;
BJU Int; 2006 Sep; 98(3):573-9. PubMed ID: 16925756
[TBL] [Abstract][Full Text] [Related]
12. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
Klotz L
Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
[TBL] [Abstract][Full Text] [Related]
13. Active surveillance for the management of prostate cancer in a contemporary cohort.
Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
[TBL] [Abstract][Full Text] [Related]
14. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer.
Loeb S; Smith ND; Roehl KA; Catalona WJ
Urology; 2007 Jun; 69(6):1170-5. PubMed ID: 17572209
[TBL] [Abstract][Full Text] [Related]
15. [Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].
Leibovici D; Lindner A; Stay K; Zisman A
Harefuah; 2006 Oct; 145(10):763-7, 781, 780. PubMed ID: 17111715
[TBL] [Abstract][Full Text] [Related]
16. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
[TBL] [Abstract][Full Text] [Related]
17. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
18. [Staging and therapeutic options in local prostatic carcinoma].
Stoffel F; Forster T; Gasser TC
Ann Ital Chir; 1999; 70(5):665-70. PubMed ID: 10692785
[TBL] [Abstract][Full Text] [Related]
19. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
20. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis.
Mold JW; Holtgrave DR; Bisonni RS; Marley DS; Wright RA; Spann SJ
J Fam Pract; 1992 May; 34(5):561-8. PubMed ID: 1578205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]